XenaCare Announces Exclusive License to Market and Distribute a Cellular Cleanse and Detoxification Product

DELRAY BEACH, Fla.--(Business Wire)--
XenaCare Holdings Inc. (OTCBB:XCHO), a company specializing in the marketing and
retail distribution of consumer healthcare products has announced today that it
has received the exclusive license to market and distribute a cellular cleanse
and detoxification product designed as an effective solution for removing heavy
metals and toxins from the body. Research has also shown that the product`s
ingredients may help reduce viral replication and support healthy blood sugar
levels. Additionally, this product improves nutrient absorption, supports immune
system function and reduces symptoms of allergies.

"Over the last few years, consumers have become increasingly aware of the
significant health issues associated with environmental toxins," commented Frank
Rizzo, President of XenaCare Holdings. "We believe that our product provides an
effective solution for reducing these health conditions and we are optimistic
that it will quickly become a leading product in the market," he added.

The Detoxification market is one of the fastest growing nutritional markets in
the U.S. with current estimates at over $4 billion annually. Many of these
products include digestive cleansers that act mostly as laxatives. XenaCare`s
new product is unique in its ability to detoxify the entire body - not just the
digestive system.

On Monday, XenaCare announced an exclusive license to market and distribute an
FDA-approved product for the treatment of chronic pain. Additionally, the
Company announced that is has launched the SunPill, a dietary supplement that
helps the skin protect itself from the harmful rays of the sun. The SunPill is
currently available at RiteAid, CVS.comDrugstore.com and Amazon.com.

XenaCare is preparing to Release a skin care product called Pro Dermex for use
in Dermatologists offices for healthier skin and reduction of skin damage caused
by the Sun. The product will be actively marketed to the 16,000 practicing
Dermatologists in the U.S., with a focus on the 2,500 stocking Dermatologists.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases
"would be," "will allow," "intends to," "will likely result," "are expected to,"
"will continue," "is anticipated," "estimate," "project," or similar expressions
are intended to identify "forward-looking statements." Actual results could
differ materially from those projected in XenaCare Holding`s ("the Company")
business plan. The Company's business is subject to various risks, which are
discussed in the Company's filings with the Securities and Exchange Commission
("SEC").Receiving an exclusive marketing and distribution license for the
detoxification product should not be construed as an indication in any way
whatsoever of the value of the Company or its common stock.The Company's filings
may be accessed at the SEC's Edgar system at www.sec.gov.Statements made herein
are as of the date of this press release and should not be relied upon as of any
subsequent date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not undertake,
and we specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.

XenaCare Holdings, Inc.
Frank Rizzo, 561-496-6676
FRizzo@XenaCare.com

Copyright Business Wire 2009